Ardevora Asset Management LLP Sells 805,791 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
Ardevora Asset Management LLP Sells 805,791 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
Ardevora Asset Management LLP reduced its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) by 47.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 905,303 shares of the company's stock after selling 805,791 shares during the quarter. Ardevora Asset Management LLP owned 0.35% of Maravai LifeSciences worth $23,112,000 at the end of the most recent reporting period.
根据Ardevora Asset Management LLP提交给美国证券交易委员会(SEC)的最新Form 13F文件，该公司在第三季度减持了Maravai LifeSciences Holdings，Inc.(纳斯达克代码：MRVI-GET Rating)的股票47.1%。该基金在本季度出售了805,791股后，持有该公司905,303股股票。Ardevora Asset Management LLP在最近一个报告期结束时拥有Maravai LifeSciences 0.35%的股份，价值23,112,000美元。
A number of other hedge funds have also recently made changes to their positions in MRVI. Bank of New York Mellon Corp lifted its position in shares of Maravai LifeSciences by 1.5% during the first quarter. Bank of New York Mellon Corp now owns 416,617 shares of the company's stock valued at $14,694,000 after purchasing an additional 6,339 shares in the last quarter. Bank of Montreal Can lifted its position in shares of Maravai LifeSciences by 13.6% during the first quarter. Bank of Montreal Can now owns 16,563 shares of the company's stock valued at $591,000 after purchasing an additional 1,986 shares in the last quarter. MetLife Investment Management LLC bought a new position in shares of Maravai LifeSciences during the first quarter valued at about $250,000. Dimensional Fund Advisors LP lifted its position in shares of Maravai LifeSciences by 534.6% during the first quarter. Dimensional Fund Advisors LP now owns 117,159 shares of the company's stock valued at $4,133,000 after purchasing an additional 98,698 shares in the last quarter. Finally, Sei Investments Co. lifted its position in shares of Maravai LifeSciences by 7.5% during the first quarter. Sei Investments Co. now owns 159,229 shares of the company's stock valued at $5,554,000 after purchasing an additional 11,079 shares in the last quarter. 48.67% of the stock is currently owned by institutional investors and hedge funds.
其他一些对冲基金最近也对它们在MRVI的头寸进行了调整。纽约梅隆银行(Bank Of New York Mellon Corp)在第一季度将其在Maravai LifeSciences股票的头寸提高了1.5%。纽约梅隆银行(Bank Of New York Mellon Corp)目前持有416,617股该公司股票，价值14,694,000美元，此前该公司在上个季度又购买了6,339股。蒙特利尔银行可以在第一季度将其在Maravai LifeSciences的股票头寸提高13.6%。蒙特利尔银行在上个季度又购买了1,986股后，现在可以持有16,563股该公司股票，价值591,000美元。大都会人寿投资管理公司在第一季度购买了Maravai LifeSciences的新头寸，价值约25万美元。Dimensional Fund Advisors LP在第一季度将其在Maravai LifeSciences的股票头寸提高了534.6%。Dimension Fund Advisors LP在上个季度额外购买了98,698股后，现在拥有117,159股该公司的股票，价值4,133,000美元。最后，Sei Investments Co.在第一季度将Maravai LifeSciences股票的持仓量提高了7.5%。SEI Investments Co.目前持有159,229股该公司股票，价值5,554,000美元，上一季度又购买了11,079股。48.67%的股票目前由机构投资者和对冲基金持有。
Maravai LifeSciences Stock Up 3.3 %
Maravai LifeSciences股价上涨3.3%
NASDAQ MRVI opened at $14.51 on Tuesday. The business has a fifty day moving average price of $14.01 and a 200 day moving average price of $19.36. Maravai LifeSciences Holdings, Inc. has a one year low of $12.16 and a one year high of $41.82. The company has a debt-to-equity ratio of 0.62, a quick ratio of 6.68 and a current ratio of 7.22. The company has a market cap of $3.70 billion, a P/E ratio of 8.11 and a beta of -0.25.
周二，纳斯达克MRVI开盘报14.51美元。该业务的50日移动平均价为14.01美元，200日移动平均价为19.36美元。Maravai LifeSciences Holdings，Inc.的一年低点为12.16美元，一年高位为41.82美元。该公司的负债权益比率为0.62，速动比率为6.68，流动比率为7.22。该公司的市值为37亿美元，市盈率为8.11，贝塔系数为-0.25。
Analysts Set New Price Targets
分析师设定新的价格目标
A number of research firms recently weighed in on MRVI. The Goldman Sachs Group dropped their price target on shares of Maravai LifeSciences from $18.00 to $16.00 and set a "buy" rating on the stock in a research report on Tuesday, January 17th. Royal Bank of Canada assumed coverage on shares of Maravai LifeSciences in a report on Tuesday, December 6th. They set an "outperform" rating and a $22.00 price target on the stock. Deutsche Bank Aktiengesellschaft started coverage on shares of Maravai LifeSciences in a research note on Tuesday, December 13th. They set a "buy" rating and a $25.00 target price on the stock. Bank of America lowered shares of Maravai LifeSciences from a "buy" rating to a "neutral" rating and cut their price objective for the company from $32.00 to $17.00 in a report on Thursday, November 3rd. Finally, UBS Group lowered shares of Maravai LifeSciences from a "buy" rating to a "neutral" rating and cut their target price for the company from $20.00 to $16.00 in a report on Thursday, January 5th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $23.00.
一些研究公司最近加入了MRVI的研究。1月17日，在一份周二的研究报告中，高盛夫妇将马拉威生命科学公司的股票目标价从18.00美元下调至16.00美元，并对该股设定了“买入”评级。加拿大皇家银行在12月6日星期二的一份报告中对马拉威生命科学的股票进行了报道。他们为该股设定了“跑赢大盘”的评级和22.00美元的目标价。德意志银行Aktiengesellschaft在12月13日星期二的一份研究报告中开始报道Maravai LifeSciences的股票。他们为该股设定了“买入”评级和25.00美元的目标价。在11月3日周四的一份报告中，美国银行将Maravai LifeSciences的股票评级从买入下调至中性，并将该公司的目标价从32.00美元下调至17.00美元。最后，瑞银集团在1月5日周四的一份报告中，将Maravai LifeSciences的股票评级从买入下调至中性，并将该公司的目标价从20.00美元下调至16.00美元。两名投资分析师对该股的评级为持有，六名分析师对该公司股票的评级为买入。根据MarketBeat.com的数据，该股目前的普遍评级为“适度买入”，平均目标价为23.00美元。
About Maravai LifeSciences
关于Maravai LifeSciences
(Get Rating)
(获取评级)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Maravai LifeSciences控股公司是一家生命科学公司，提供能够在美国和国际上开发药物疗法、诊断、新型疫苗和支持人类疾病研究的产品。该公司的产品涉及生物制药开发的关键阶段，包括用于诊断和治疗应用的核酸、在生物制药产品生产过程中检测杂质的基于抗体的产品，以及检测各种组织中蛋白质表达的产品。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Maravai LifeSciences (MRVI)
- Intuit Is About To Make a Move, But Which Way?
- 3 Late January Earnings Plays With Pop Potential
- Low-Priced Stocks Still Paying Dividends
- Why is the Chipotle Stock Price Surging This Week?
- Is the Northrop Grumman Selloff an Opportunity?
- 免费获取StockNews.com关于Maravai LifeSciences(MRVI)的研究报告
- Intuit即将采取行动，但走哪条路呢？
- 1月下旬收益表现出流行音乐的潜力
- 低价股仍在派发股息
- 为什么Chipotle的股价本周飙升？
- 诺斯罗普·格鲁曼公司的抛售是一个机会吗？
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Maravai生命科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Maravai LifeSciences和相关公司的最新新闻和分析师评级的每日简要摘要。